lupus erythematosus, systemic

Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments
Zoé Gendebien, Christian von Frenckell, Clio Ribbens, Béatrice André, Marie Thys, Marjorie Gangolf, Laurence Seidel, Michel G Malaise, Olivier Malaise

Annals of the Rheumatic Diseases Jun 2021, 80 (6) e94; DOI: 10.1136/annrheumdis-2020-218244
Response to: ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ by Györfi et al
Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson

Annals of the Rheumatic Diseases Jun 2021, 80 (6) e88; DOI: 10.1136/annrheumdis-2020-218328
Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences
Jun Zhao, Rongrong Pang, Jian Wu, Yanju Guo, Yang Yang, Libo Zhang, Xinyi Xia

Annals of the Rheumatic Diseases May 2021, 80 (5) e63; DOI: 10.1136/annrheumdis-2020-218183
COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine
Cheng Lay Teh, Yaw Kiet Cheong, Wan Rosmaiza Wan Musa, Sharifah Aishah Wan Mohd Akbar, Noraini Mat Husin, Suk Chyn Gun

Annals of the Rheumatic Diseases May 2021, 80 (5) e69; DOI: 10.1136/annrheumdis-2020-218154
Response to: ‘Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India’ by Goyal et al
Alexis Mathian, Zahir Amoura

Annals of the Rheumatic Diseases May 2021, 80 (5) e72; DOI: 10.1136/annrheumdis-2020-218146
Response to: ‘The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients’ by Favalli et al
Vasco C Romão, Ana Rita Cruz-Machado, João Eurico Fonseca

Annals of the Rheumatic Diseases May 2021, 80 (5) e76; DOI: 10.1136/annrheumdis-2020-218175
Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus
Yasushi Kondo, Yuko Kaneko, Tatsuhiro Oshige, Hiroyuki Fukui, Shuntaro Saito, Mikio Okayama, Hirofumi Kamata, Makoto Ishii, Naoki Hasegawa, Koichi Fukunaga, Tsutomu Takeuchi

Annals of the Rheumatic Diseases May 2021, 80 (5) e77; DOI: 10.1136/annrheumdis-2020-218157
Response to: ‘Telemedicine will not keep us apart in the COVID-19 pandemic’ by Perniola et al
Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna

Annals of the Rheumatic Diseases Apr 2021, 80 (4) e49; DOI: 10.1136/annrheumdis-2020-218071
Response to: ‘COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases’ by Lopez-Medina et al
Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna

Annals of the Rheumatic Diseases Apr 2021, 80 (4) e51; DOI: 10.1136/annrheumdis-2020-218070
Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey
Marlene Plüß, Gamal Chehab, Peter Korsten

Annals of the Rheumatic Diseases Apr 2021, 80 (4) e52; DOI: 10.1136/annrheumdis-2020-217967

Main menu

lupus erythematosus, systemic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

lupus erythematosus, systemic

Pages